2025
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024
Lewis N, Harker E, Cleary S, Zhu Y, Grijalva C, Chappell J, Rhoads J, Baughman A, Casey J, Blair P, Jones I, Johnson C, Halasa N, Lauring A, Martin E, Gaglani M, Ghamande S, Columbus C, Steingrub J, Duggal A, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Ferguson S, Mosier J, Qadir N, Chang S, Ginde A, Zepeski A, Mallow C, Harris E, Johnson N, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, Surie D, Dawood F, Ellington S, Self W. Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024. The Journal Of Infectious Diseases 2025, jiaf185. PMID: 40198276, DOI: 10.1093/infdis/jiaf185.Peer-Reviewed Original ResearchAcute respiratory illnessVaccine effectivenessInfluenza virusDays prior to illness onsetInfluenza-associated hospitalizationsTest-negative designSentinel Surveillance NetworkImmunocompetent patientsInfluenza BInfluenza seasonImmunocompromised patientsInfluenza casesB virusInfluenzaIllness onsetPatientsRespiratory illnessMedical CenterSARS-CoV-2VaccineSurveillance networkElevated activityHospitalDaysVirusPhospholipid scramblase 1: a frontline defense against viral infections
Yang A, Norbrun C, Sorkhdini P, Zhou Y. Phospholipid scramblase 1: a frontline defense against viral infections. Frontiers In Cellular And Infection Microbiology 2025, 15: 1573373. PMID: 40248364, PMCID: PMC12003403, DOI: 10.3389/fcimb.2025.1573373.Peer-Reviewed Original ResearchConceptsPhospholipid scramblase 1Human immunodeficiency virusInfluenza A virusToll-like receptor 9Human T-cell leukemia virus type 1Epstein-Barr virusHepatitis B virusInterferon-stimulated genesViral infectionHuman cytomegalovirusVirus type 1Antiviral activityTranslocation of phospholipidsFrontline defenseTransactivation of human immunodeficiency virusImmunodeficiency virusActivation of JAK/STAT pathwayImmune cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2A virusB virusReceptor 9Respiratory syndrome coronavirus 2Entry of severe acute respiratory syndrome coronavirus 2PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus
Li Y, Ma H, Zhang Y, He T, Li B, Ren H, Feng J, Sheng J, Li K, Qian Y, Wang Y, Zhao H, He J, Li H, Wu H, Yao Y, Shi M. PGLYRP2 drives hepatocyte-intrinsic innate immunity by trapping and clearing hepatitis B virus. Journal Of Clinical Investigation 2025, 135: e188083. PMID: 39946201, PMCID: PMC11996887, DOI: 10.1172/jci188083.Peer-Reviewed Original ResearchHepatitis B virusHBV clearanceSpontaneous clearance of hepatitis B virusB virusClear hepatitis B virusClearance of hepatitis B virusHepatitis B virus infectionSpontaneous HBV clearanceAnti-HBV treatmentDNA-binding domainInhibit HBV replicationCovalently closed circular DNAPattern recognition receptorsPotential therapeutic strategyFunctional cureSpontaneous clearanceHost-virus interactionsAge-dependent expressionPathogenic variantsPGRP domainHBV replicationTherapeutic strategiesRecognition receptorsNucleocytoplasmic translocationPGLYRP2
2024
Channel width modulates the permeability of DNA origami–based nuclear pore mimics
Feng Q, Saladin M, Wu C, Cao E, Zheng W, Zhang A, Bhardwaj P, Li X, Shen Q, Kapinos L, Kozai T, Mariappan M, Lusk C, Xiong Y, Lim R, Lin C. Channel width modulates the permeability of DNA origami–based nuclear pore mimics. Science Advances 2024, 10: eadq8773. PMID: 39536094, PMCID: PMC11559598, DOI: 10.1126/sciadv.adq8773.Peer-Reviewed Original ResearchHepatitis B
Khungar V, Han T. Hepatitis B. 2024, 227-235. DOI: 10.1201/9781003524489-36.Peer-Reviewed Original ResearchAccuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Patel K, Asrani S, Fiel M, Levine D, Leung D, Duarte-Rojo A, Dranoff J, Nayfeh T, Hasan B, Taddei T, Alsawaf Y, Saadi S, Majzoub A, Manolopoulos A, Alzuabi M, Ding J, Sofiyeva N, Murad M, Alsawas M, Rockey D, Sterling R. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline. Hepatology 2024, 81: 358-379. PMID: 38489517, DOI: 10.1097/hep.0000000000000842.Peer-Reviewed Original ResearchAminotransferase-to-platelet ratio indexChronic liver diseaseNonalcoholic fatty liver diseaseHepatitis B virusBlood-based biomarkersLiver diseaseFIB-4HIV-HCV co-infectionCo-InfectionFIB-4 <Alternative to liver biopsyFIB-4 >Pre-test probabilityBlood-based testLiver disease assessmentSystematic reviewStaging liver fibrosisComprehensive search of databasesHIV-HCVFatty liver diseaseProportional odds ratiosAdvanced fibrosisLiver biopsyViral hepatitisB virus
2023
Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010–19: a repeated cross-sectional study
Sumner K, Masalovich S, O’Halloran A, Holstein R, Reingold A, Kirley P, Alden N, Herlihy R, Meek J, Yousey-Hindes K, Anderson E, Openo K, Monroe M, Leegwater L, Henderson J, Lynfield R, McMahon M, McMullen C, Angeles K, Spina N, Engesser K, Bennett N, Felsen C, Lung K, Shiltz E, Thomas A, Talbot H, Schaffner W, Swain A, George A, Rolfes M, Reed C, Garg S. Severity of influenza-associated hospitalisations by influenza virus type and subtype in the USA, 2010–19: a repeated cross-sectional study. The Lancet Microbe 2023, 4: e903-e912. PMID: 37769676, PMCID: PMC10872935, DOI: 10.1016/s2666-5247(23)00187-8.Peer-Reviewed Original ResearchConceptsInfluenza virus typeInfluenza-associated hospitalisationsInfluenza seasonInfluenza B virusICU admissionMechanical ventilationSevere outcomesOdds ratioVirus typeFluSurv-NETECMO useInfluenza vaccineB virusVirus infectionLaboratory-confirmed influenza virus infectionInfluenza Hospitalization Surveillance NetworkInfluenza B virus infectionPopulation-based surveillance systemComplete chart reviewEarly antiviral treatmentHospital-onset casesInfluenza-associated outcomesRepeated cross-sectional studyInfluenza vaccination statusB virus infectionAssessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
Castro D, Prajapati S, Feng M, Chan E, Lee K, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Ebrahimi H, Govindarajan A, Meza L, Mercier B, Chawla N, Dizman N, Philip E, Hsu J, Bergerot C, Chehrazi‐Raffle A, Rock A, Liu S, Tripathi A, Dorff T, Pal S. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy. BJU International 2023, 133: 297-304. PMID: 37548533, DOI: 10.1111/bju.16148.Peer-Reviewed Original ResearchHBV/HCV infectionExclusion of patientsHepatitis B virusConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionSystemic therapyRCC trialsVirus infectionExact testHepatitis C virus infectionHuman immunodeficiency virus (HIV) infectionC virus infectionImmunodeficiency virus infectionFisher's exact testRestrictive eligibility criteriaContext of HIVChi-square testPrevalent comorbiditiesHIV infectionImmunotherapy trialsPatient populationB virusTrial characteristicsImplementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter L, Danve A. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care & Research 2023, 77: 273-281. PMID: 37382043, DOI: 10.1002/acr.25181.Peer-Reviewed Original ResearchBest practice advisoryHepatitis B virusAutoimmune rheumatic diseasesBPA implementationSynthetic disease-modifying antirheumatic drugsDisease-modifying antirheumatic drugsHepatitis C virus infectionHepatitis B surface antigenC virus infectionUse of biologicsB surface antigenQuality improvement initiativesElectronic health recordsEligible patientsAntirheumatic drugsRheumatic diseasesRheumatology practiceSociety guidelinesB virusPractice advisoryComputerized decision support systemVirus infectionRoutine screeningPatient screeningPatientsPay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial
Zhang Y, Li J, Xie Y, Wu D, Ong J, Marley G, Kamarulzaman A, Lu H, Zou F, Smith J, Tucker J, Fu G, Tang W. Pay-it-forward incentives for hepatitis virus testing in men who have sex with men: a cluster randomized trial. Nature Medicine 2023, 29: 2241-2247. PMID: 37640859, DOI: 10.1038/s41591-023-02519-w.Peer-Reviewed Original ResearchConceptsHepatitis B virusCare armHCV testingVirus testingTwo-arm cluster-randomized trialHepatitis C virus testingHepatitis virus testingCluster-randomized trialProportion of menGroup of menAdverse eventsHBV testPrimary outcomeB virusForward armFree testingHCVMenRapid testingSexTrialsArmActive community participationTestingPersonsPrevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis
Aghaei A, Gholami J, Sangchooli A, Rostam-Abadi Y, Olamazadeh S, Ardeshir M, Baheshmat S, Shadloo B, Taj M, Saeed K, Rahimi-Movaghar A. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis. The Lancet Global Health 2023, 11: e1225-e1237. PMID: 37474230, DOI: 10.1016/s2214-109x(23)00267-x.Peer-Reviewed Original ResearchConceptsPrevalence of injection drug useInjection drug usePrevalence of HIVHepatitis B virusHepatitis C virusB virusC virusMeta-analysisSystematic reviewHepatitis C virus infection ratesEastern Mediterranean RegionCharacteristics of peopleDrug useHIV infection ratesOpioid agonist treatmentInfection rateProgramme servicesPopulation size of peopleHepatitis CAgonist treatmentHarm reduction servicesHepatitis BWHO Eastern Mediterranean RegionWeb of ScienceProvision of servicesExamining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research
Ebrahimi H, Castro D, Feng M, Prajapati S, Lee K, Chan E, Paul T, Sehgal I, Patel J, Li X, Zengin Z, Meza L, Mercier B, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot C, Rock A, Liu S, Tripathi A, Dorff T, Pal S, Chehrazi-Raffle A. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research. Clinical Genitourinary Cancer 2023, 21: e467-e473. PMID: 37301665, DOI: 10.1016/j.clgc.2023.05.013.Peer-Reviewed Original ResearchConceptsProstate cancer clinical trialsHBV/HCV infectionCancer clinical trialsHepatitis B virusClinical trialsConcurrent malignancyBrain metastasesEligibility criteriaHCV infectionHIV infectionExclusion criteriaClinical OncologyEastern Cooperative Oncology Group scaleAssessment of recommendationsECOG PS 0C virus infectionRestrictive eligibility criteriaAmerican SocietyCancer researchHCV positivityPS 0HIV positivityImmunotherapy trialsB virusVirus infectionPrevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil
Pacheco S, Schinoni M, Stocker A, Paraná R, Reis M, Silva L. Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i3.3473.Peer-Reviewed Original ResearchGenotypic resistance mutationsResistance mutationsHepatitis BChronic hepatitis BFirst-line treatmentVaccine escape mutationsHepatitis B virusChronic HBVAntiviral treatmentLine treatmentLiver diseaseTherapeutic managementB virusEscape mutationsGenotypic resistanceReference centerPatientsGenetic mutationsEntecavirHBVTenofovirTreatmentNortheast of BrazilPresent studyNucleotide analogues
2022
Attacking the public health crisis of hepatocellular carcinoma at its roots
Lee HM, Lidofsky SD, Taddei TH, Townshend‐Bulson L. Attacking the public health crisis of hepatocellular carcinoma at its roots. Hepatology 2022, 77: 1456-1459. PMID: 35989555, PMCID: PMC10026951, DOI: 10.1002/hep.32741.Peer-Reviewed Original ResearchConceptsHepatitis B virusLiver diseasePublic health crisisHepatocellular carcinomaChronic hepatitis B virusAlcohol-related liver diseaseNonalcoholic fatty liver diseaseChronic liver diseaseFatty liver diseasePrincipal risk factorsCancer-related deathSignificant mortality ratePrevention of HCCHealth crisisViral hepatitisTreatment advancesB virusRisk factorsCurable stageCommon causeRisk populationsHCC detectionRisk individualsMortality rateSurveillance programMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2022, 87-104. DOI: 10.1007/978-3-030-41683-6_51.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidenceOral Cyanobacteria and Hepatocellular Carcinoma
Hernandez BY, Zhu X, Risch HA, Lu L, Ma X, Irwin ML, Lim JK, Taddei TH, Pawlish KS, Stroup AM, Brown R, Wang Z, Wong LL, Yu H. Oral Cyanobacteria and Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 221-229. PMID: 34697061, PMCID: PMC8755591, DOI: 10.1158/1055-9965.epi-21-0804.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusHepatocellular carcinomaRisk factorsLiver diseaseHCC casesOral microbiomeU.S. case-control studyIndependent risk factorChronic liver diseaseFatty liver diseaseHCC risk factorsGut microbial alterationsType 2 diabetesCase-control studyLiver cancer developmentNSAID useAspirin useC virusB virusHCC riskNegative historyOral samplesSignificant associationCancer development
2021
Metabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2021, 1-19. DOI: 10.1007/978-3-030-37482-2_51-1.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence
2020
Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review
Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. International Journal Of Infectious Diseases 2020, 104: 510-525. PMID: 33385583, PMCID: PMC11094609, DOI: 10.1016/j.ijid.2020.12.068.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHepatitis B virusHepatitis C virusPrevalence of HIVHigh prevalenceSystematic reviewSubstantial public health threatHigh-risk groupHigh-risk populationNational surveillance reportsPublic health threatHBV prevalenceHCV prevalenceHIV prevalenceImmunodeficiency virusC virusLanguage restrictionsB virusPrevalenceSurveillance reportsHealth threatVirusPublication datePWIDEMBASEHepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis
Rostam-Abadi Y, Rafiemanesh H, Gholami J, Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A. Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis. Harm Reduction Journal 2020, 17: 81. PMID: 33087141, PMCID: PMC7579800, DOI: 10.1186/s12954-020-00424-w.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis B virus infectionPrevalence of HBV infectionHepatitis B virus prevalenceHBV infectionSubgroups of PWIDHepatitis B virus surface antigenB virus infectionRandom-effects model meta-analysisMeta-analysisPrevalence of HBsAgEstimation of HBsAgHigh-risk groupSystematic reviewPooled prevalence of HBsAgHarm reduction interventionsMeta-regression analysisPositive HBsAgHistory of imprisonmentHBsAg prevalenceB virusConclusionThe prevalenceReduction interventionsAt-risk populationsHBsAgGeographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply